{
  "disease_name": "Breast cancer",
  "synonyms": [
    "Breast carcinoma",
    "Mammary carcinoma"
  ],
  "summary": "Breast cancer is a malignant tumor that develops from breast tissue, most commonly from the ducts or lobules. It may be invasive or non-invasive, with various molecular subtypes influencing prognosis and treatment response.",
  "causes": [
    "Mutations in BRCA1 and BRCA2 genes",
    "Mutations in TP53, PTEN, PALB2, and PIK3CA",
    "Hormonal imbalance and prolonged estrogen exposure",
    "Ionizing radiation exposure",
    "DNA repair defects"
  ],
  "risk_factors": [
    "Older age",
    "Female sex",
    "Family history of breast cancer",
    "Inherited BRCA1 or BRCA2 mutations",
    "Early menarche",
    "Late menopause",
    "Nulliparity or first childbirth after age 35",
    "Hormone replacement therapy",
    "Obesity",
    "Alcohol consumption",
    "Physical inactivity",
    "High-fat diet",
    "Radiation exposure to chest",
    "Dense breast tissue"
  ],
  "symptoms": [
    "Breast lump or thickening",
    "Change in breast shape or size",
    "Skin dimpling",
    "Nipple inversion",
    "Nipple discharge",
    "Red or scaly skin on breast or nipple",
    "Breast pain",
    "Swollen lymph nodes"
  ],
  "diagnosis": [
    "Mammography",
    "Ultrasound",
    "MRI",
    "Biopsy",
    "Estrogen receptor (ER), progesterone receptor (PR), and HER2 testing",
    "BRCA genetic testing",
    "Staging with TNM system"
  ],
  "treatments": [
    "Surgery (lumpectomy, mastectomy, sentinel lymph node biopsy)",
    "Radiation therapy",
    "Chemotherapy",
    "Hormone therapy (tamoxifen, aromatase inhibitors)",
    "Targeted therapy (trastuzumab, pertuzumab, lapatinib)",
    "Immunotherapy (pembrolizumab, atezolizumab)",
    "Endocrine therapy"
  ],
  "related_genes": [
    "BRCA1",
    "BRCA2",
    "TP53",
    "PTEN",
    "PALB2",
    "PIK3CA",
    "HER2 (ERBB2)",
    "GATA3"
  ],
  "subtypes": [
    {
      "name": "Ductal carcinoma",
      "typical_patients": "Adult women; can also occur in men",
      "five_year_survival": "85–90% (localized disease)",
      "common_treatments": [
        "Surgery",
        "Radiation therapy",
        "Chemotherapy"
      ]
    },
    {
      "name": "Lobular carcinoma",
      "typical_patients": "Adult women; often bilateral",
      "five_year_survival": "80–90% (localized disease)",
      "common_treatments": [
        "Surgery",
        "Hormone therapy"
      ]
    },
    {
      "name": "Triple-negative breast cancer",
      "typical_patients": "Younger women; more common in Black women",
      "five_year_survival": "77% overall; 12% with metastases",
      "common_treatments": [
        "Chemotherapy",
        "Immunotherapy"
      ]
    },
    {
      "name": "Inflammatory breast cancer",
      "typical_patients": "Women aged 40–50",
      "five_year_survival": "39% overall; 19% with metastases",
      "common_treatments": [
        "Chemotherapy",
        "Surgery",
        "Radiation therapy"
      ]
    },
    {
      "name": "HER2-positive breast cancer",
      "typical_patients": "Adults with HER2 gene amplification",
      "five_year_survival": "Varies by stage",
      "common_treatments": [
        "Trastuzumab",
        "Pertuzumab",
        "Chemotherapy"
      ]
    }
  ],
  "epidemiology": {
    "global_cases_2015": 2000000,
    "global_deaths_2015": 627000,
    "most_common_in": "Women in developed countries",
    "five_year_survival_rate": "80–90% (developed countries), lower in developing regions"
  },
  "relationships": [
    {
      "source": "Breast cancer",
      "relation": "has_symptom",
      "target": "Breast lump"
    },
    {
      "source": "Breast cancer",
      "relation": "has_symptom",
      "target": "Skin dimpling"
    },
    {
      "source": "Breast cancer",
      "relation": "has_symptom",
      "target": "Nipple inversion"
    },
    {
      "source": "Breast cancer",
      "relation": "has_risk_factor",
      "target": "Older age"
    },
    {
      "source": "Breast cancer",
      "relation": "has_risk_factor",
      "target": "Family history of breast cancer"
    },
    {
      "source": "Breast cancer",
      "relation": "has_risk_factor",
      "target": "BRCA1 mutation"
    },
    {
      "source": "Breast cancer",
      "relation": "has_risk_factor",
      "target": "Hormone replacement therapy"
    },
    {
      "source": "Breast cancer",
      "relation": "has_cause",
      "target": "BRCA1 mutation"
    },
    {
      "source": "Breast cancer",
      "relation": "has_cause",
      "target": "Estrogen exposure"
    },
    {
      "source": "Breast cancer",
      "relation": "associated_gene",
      "target": "BRCA2"
    },
    {
      "source": "Breast cancer",
      "relation": "associated_gene",
      "target": "TP53"
    },
    {
      "source": "Breast cancer",
      "relation": "associated_gene",
      "target": "PIK3CA"
    },
    {
      "source": "Breast cancer",
      "relation": "treated_with",
      "target": "Surgery"
    },
    {
      "source": "Breast cancer",
      "relation": "treated_with",
      "target": "Chemotherapy"
    },
    {
      "source": "Breast cancer",
      "relation": "treated_with",
      "target": "Hormone therapy"
    },
    {
      "source": "Breast cancer",
      "relation": "treated_with",
      "target": "Targeted therapy"
    },
    {
      "source": "Breast cancer",
      "relation": "treated_with",
      "target": "Immunotherapy"
    },
    {
      "source": "Ductal carcinoma",
      "relation": "subtype_of",
      "target": "Breast cancer"
    },
    {
      "source": "Lobular carcinoma",
      "relation": "subtype_of",
      "target": "Breast cancer"
    },
    {
      "source": "Triple-negative breast cancer",
      "relation": "subtype_of",
      "target": "Breast cancer"
    },
    {
      "source": "Inflammatory breast cancer",
      "relation": "subtype_of",
      "target": "Breast cancer"
    },
    {
      "source": "HER2-positive breast cancer",
      "relation": "subtype_of",
      "target": "Breast cancer"
    }
  ]
}